|Bid||38.25 x 3200|
|Ask||38.65 x 900|
|Day's range||38.25 - 39.64|
|52-week range||37.54 - 151.80|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||16 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||69.61|
The announcement will not affect UK vaccine supply.
What happened Shares of CureVac (NASDAQ: CVAC) were tumbling 7.4% as of 11 a.m. EDT on Tuesday after falling as much as 13% earlier in the morning. The decline came after the company announced it's withdrawing COVID-19 vaccine candidate CVnCoV from the European Medicines Agency's approval process.
DGAP-News: CureVac / Key word(s): Strategic Company Decision12.10.2021 / 13:02 The issuer is solely responsible for the content of this announcement.CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology- COVID-19 vaccine efforts to be re-allocated to accelerate the development of second-generation program in collaboration with GSK- First-generation vaccine candidate, CVnCoV, to be withdrawn from regulatory review due to potential overlap with approval timeli